Johnson & Johnson (JNJ) and Eli Lilly (LLY): Weighing Stability Against High-Growth Potential
Key Takeaways
- Johnson & Johnson pairs diversified healthcare operations with a 64-year dividend-increase streak, while Eli Lilly offers faster, GLP-1-driven growth.
- JNJ is delivering steady, single-to-low-double-digit revenue growth as newer oncology and immunology drugs offset the Stelara patent cliff.
- LLY is compounding revenue at roughly 50% year over year, powered by Mounjaro, Zepbound, and the newly launched oral pill Foundayo.
- Relative performance diverges sharply on valuation: JNJ trades near 23 times forward earnings, while LLY trades near 38 times earnings.
- Sentiment favors LLY on momentum and growth catalysts, while JNJ offers comparatively defensive, income-oriented positioning.
Setting the Stage for Two Distinct Healthcare Plays
Johnson & Johnson (JNJ) and Eli Lilly (LLY) stand out as major healthcare holdings, yet they follow quite different strategies. JNJ functions as a broad healthcare player across pharmaceuticals and medical technology, valued for its consistency and long dividend history. LLY focuses squarely on pharmaceuticals and has become central to the surge in GLP-1 therapies for obesity and diabetes. This comparison looks at how the two stack up in terms of momentum, valuation, risk, and overall positioning, giving both growth-oriented and income-focused investors a clearer sense of which approach may align better with their goals right now.
JNJ’s Recent Results and Business Mix
JNJ runs two main segments: Innovative Medicine for prescription drugs and MedTech for devices and equipment. Shares have gained solid ground over the past year and sit near record levels. First-quarter 2026 revenue climbed 9.9% year over year to about $24.1 billion, supported by oncology treatments such as Darzalex and Carvykti, the immunology drug Tremfya, and neuroscience products like Spravato. That performance helped counter the sharp drop in Stelara sales after biosimilar competition arrived. Management raised its full-year target to roughly $100.8 billion in revenue at the midpoint and extended its dividend streak to 64 straight years, underscoring its Dividend King status. A top-tier AAA credit rating adds support, though talc litigation continues as a lingering concern. The stock now trades above its longer-term average multiple.
LLY’s Momentum and Portfolio Expansion
Eli Lilly’s growth has been reshaped by its incretin lineup, anchored by Mounjaro for type 2 diabetes and Zepbound for obesity. Shares have climbed sharply to new highs amid sustained demand for GLP-1 products. First-quarter 2026 revenue jumped 56% year over year to roughly $19.8 billion, with adjusted EPS also beating expectations. The company added Foundayo, its first once-daily oral GLP-1 pill, and expanded Medicare coverage for its obesity medicines. Positive data on late-stage candidate retatrutide and several acquisitions aimed at broadening the pipeline beyond obesity round out the picture. Full-year guidance was lifted to $82–85 billion in revenue. Sentiment stays positive overall, though investors continue to monitor price erosion and the premium valuation near 38 times earnings.
Side-by-Side Assessment
The clearest differences appear in business models and growth trajectories. JNJ’s spread across oncology, immunology, neuroscience, and medical devices creates several revenue streams and softens the blow from any single product setback. LLY remains more concentrated, with Mounjaro and Zepbound driving most of its revenue and bringing both strong upside and heightened exposure to pricing shifts or new competition. On momentum, LLY leads with revenue growth near 50% year over year compared with JNJ’s high-single-digit pace. Valuation reflects the trade-off: LLY carries a sizable premium to the broader market, while JNJ, despite some re-rating, holds a more moderate multiple and delivers roughly a 2% dividend yield. Risk profiles also vary—JNJ contends with litigation and patent pressures, whereas LLY faces concentration risk, realized-price declines, and rivals in the weight-loss space. Sector exposure differs too, with JNJ gaining some buffer from medical technology and LLY staying a pure pharmaceutical growth story.
AI-Assisted Perspective on the Pair
From what I see, momentum and trend consistency point toward LLY given its stronger revenue trajectory, repeated earnings beats, and upcoming catalysts such as Foundayo’s rollout and retatrutide progress. At the same time, JNJ’s greater stability, reliable income stream, and diversified cash flows may suit more conservative allocations. Any relative preference ultimately hinges on the chosen timeframe and risk settings, but on a momentum-focused basis LLY currently shows the more consistent positive trend. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Using Tickeron’s Trending AI Robots for Further Insight
When evaluating names like JNJ and LLY, I sometimes turn to Tickeron’s Trending AI Robots page to review its AI trading bots. The platform hosts hundreds of bots that trade thousands of tickers, but only those best suited to current conditions appear in the curated section. These bots differ in style, strategy, timeframe, performance metrics, and the tickers they track, so no single option works for every situation. Reviewing the page helps compare results and choose tools that match specific objectives. Trending AI Robots
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
LLY's RSI Oscillator climbs out of oversold territory
The RSI Oscillator for LLY moved out of oversold territory on September 14, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 23 similar instances when the indicator left oversold territory. In 18 of the 23 cases the stock moved higher. This puts the odds of a move higher at 78%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 43 of 57 cases where LLY's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 75%.
The Moving Average Convergence Divergence (MACD) for LLY just turned positive on October 07, 2026. Looking at past instances where LLY's MACD turned positive, the stock continued to rise in 30 of 45 cases over the following month. The odds of a continued upward trend are 67%.
LLY moved above its 50-day moving average on October 09, 2026 date and that indicates a change from a downward trend to an upward trend.
Following a +3.99% 3-day Advance, the price is estimated to grow further. Considering data from situations where LLY advanced for three days, in 262 of 375 cases, the price rose further within the following month. The odds of a continued upward trend are 70%.
The Aroon Indicator entered an Uptrend today. In 222 of 303 cases where LLY Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 73%.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on October 08, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on LLY as a result. In 55 of 83 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 66%.
The 10-day moving average for LLY crossed bearishly below the 50-day moving average on September 04, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 10 of 13 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 77%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where LLY declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 55%.
Fundamental Analysis (Ratings)
The Tickeron Profit vs. Risk Rating rating for this company is 10 (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 63, placing this stock better than average.
The Tickeron SMR rating for this company is 14 (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Seasonality Score of 29 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Price Growth Rating for this company is 41 (best 1 - 100 worst), indicating steady price growth. LLY’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 51 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (31.153) is normal, around the industry mean (19.199). P/E Ratio (39.771) is within average values for comparable stocks, (34.793). Projected Growth (PEG Ratio) (1.170) is also within normal values, averaging (5.738). LLY has a moderately low Dividend Yield (0.006) as compared to the industry average of (0.025). LLY's P/S Ratio (12.804) is very high in comparison to the industry average of (4.033).
The Tickeron PE Growth Rating for this company is 58 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a manufacturer of pharmaceutical products
Industry PharmaceuticalsMajor
Advertisement